The study, which evaluates the safety and preliminary efficacy of ISM6331, focuses on the Hippo signaling pathway—a biological mechanism frequently implicated in therapeutic resistance. Small-molecule inhibition of this pathway has historically proven difficult, but Insilico’s platform, Chemistry42, was used to design the inhibitor specifically to address these medicinal chemistry hurdles.
In section Releases
Insilico Medicine to Present AI-Designed Cancer Drug Data at ESMO 2026
A novel AI-generated inhibitor, ISM6331, is set to take center stage at the upcoming European Society for Medical Oncology Congress in Madrid. Insilico Medicine will present first-in-human data from a Phase 1 trial, marking a significant step in the company's efforts to treat mesothelioma and advanced solid tumors.
Feng Ren, Co-CEO and Chief Scientific Officer, noted that the Rapid Oral presentation selection underscores the potential of generative AI to tackle complex oncogenic drivers. The clinical data, categorized under abstract #997, is scheduled for discussion on October 25, 2026, in the Cordoba Auditorium. Halle Zhang, Vice President of Clinical Development, emphasized that the trial aims to provide new options for patients who currently face limited alternatives for Hippo-driven malignancies. The ongoing global study continues to assess pharmacokinetics and antitumor activity to guide future development phases.
Comments (0)
No comments yet. Be the first!